Sporadic RCC: Abnormalities in histone-modifying genes

Ruhee Dere, Thai H. Ho

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Renal cell carcinoma (RCC) is one of the top ten leading causes of cancer death, affecting more than 50,000 patients annually. The median survival of patients with metastatic disease is approximately 2 years with systemic therapy, and the most common histology is clear cell renal cell carcinoma (ccRCC). The molecular mechanism is linked to the inactivation of the von Hippel-Lindau tumor suppressor gene (VHL), which encodes for an oxygen sensor that regulates degradation of the HIF (hypoxia-inducible factor) transcription factor (Latif et al., Science 260(5112):1317-1320, 1993). HIF transactivates target genes involved in cellular adaptation to hypoxia. The mammalian target of rapamycin (mTOR) signaling cascade is often stimulated in ccRCC, and activation of the mTOR kinase pathway further augments HIF levels to subsequently activate HIF-dependent transcription (Barthelemy et al., Crit Rev Oncol Hematol 88(1):42-56, 2013). The elucidation of VHL function and mTOR pathway activation led to the discovery of VEGF and mTOR inhibitors for RCC treatment. Recently, secondary mutations identified in histone-modifying enzymes suggest that chromatin remodeling and alterations of histone modifications may play a role in RCC pathogenesis and prognosis with distinct epigenetic phenotypes. This chapter will focus on summarizing the more prevalent genetic mutations and possible aberrant signaling pathways that contribute to metastatic ccRCC.

Original languageEnglish (US)
Title of host publicationRenal Cell Carcinoma
Subtitle of host publicationMolecular Targets and Clinical Applications
PublisherSpringer New York
Pages153-165
Number of pages13
ISBN (Electronic)9781493916221
ISBN (Print)9781493916214
DOIs
StatePublished - Jan 1 2015

Keywords

  • BAP1
  • Epigenetics
  • PBRM1
  • Renal cell carcinoma
  • SETD2

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Sporadic RCC: Abnormalities in histone-modifying genes'. Together they form a unique fingerprint.

  • Cite this

    Dere, R., & Ho, T. H. (2015). Sporadic RCC: Abnormalities in histone-modifying genes. In Renal Cell Carcinoma: Molecular Targets and Clinical Applications (pp. 153-165). Springer New York. https://doi.org/10.1007/978-1-4939-1622-1_6